SEC Comment Letter for NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Sep 3, 2015
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Sept. 3, 2015 · CIK: 0001389545 · Accession: 0000000000-15-044367
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-33678
Letter
Mail Stop 4720 September 3, 2015 Via E -mail Ramin Najafi Chief Executive Officer NovaBay Pharmaceuticals, Inc. 5980 Horton Street, Suite 550 Emeryville, California 94608
Re: NovaBay Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on August 21, 2015 File No. 001-33678
Dear Mr. Najafi:
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Bryan J. Pitko for
Show Raw Text
Mail Stop 4720 September 3, 2015 Via E -mail Ramin Najafi Chief Executive Officer NovaBay Pharmaceuticals, Inc. 5980 Horton Street, Suite 550 Emeryville, California 94608 Re: NovaBay Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on August 21, 2015 File No. 001-33678 Dear Mr. Najafi: We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Bryan J. Pitko for Suzanne Hayes Assistant Director